Discusses the financial collapse of many biotechnology companies in the United States in 2002. Increased investor interest in biotechnology due to the explosion of interest in anything genomic; Ways in which new biotechnology companies fueled the demand for equipment from various suppliers; Ways for investors to determine if their investment will survive.